Breaking News

DPT Completes Corrective Actions

March 20, 2013

FDA closes out investigation of Lakewood site

DPT Laboratories has received notification from the FDA on February 19, 2013, signaling the completion of DPT’s corrective actions taken at its Lakewood, NJ facility in response to the warning letter received on August 27, 2012. The letter also communicated that the Lakewood site is compliant with FDA regulations.
 
“We are pleased to have this issue behind us and appreciate the confidence our new and existing customers demonstrated in us during this time,” said Eugene Ciolfi, DPT vice president and general manager.  “I am excited and optimistic about the opportunities ahead of us in 2013.”
 
“This resolution has strengthened DPT,” said Paul Johnson, DPT Group president and chief operating officer. “Our commitment to quality and continuous improvement will remain a priority as we continue building a world-class business.”

Related Compliance:

blog comments powered by Disqus
  • Quality Risk Management

    Quality Risk Management

    Cheryl Abernathy and Bryan Sasbon, Quality Assurance Operations Manager, Ropack Pharma Solutions; QA Director & Regulatory Affairs, Ropack Pharma Solutions||September 8, 2016
    Embracing the process as a means to a strong quality culture

  • Staying Ahead in the Small Molecule Space

    Staying Ahead in the Small Molecule Space

    Dr. Matthew Moorcroft, VP Global Marketing, Cambrex||September 8, 2016
    Understand what is happening in the market and react accordingly

  • FDA & Drug Development

    FDA & Drug Development

    Rachelle Du2019Souza, Regulatory Heights Inc.||September 8, 2016
    You must perform the necessary due diligence to stay on top of regulatory developments